Results 21 to 30 of about 70,305 (361)

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients The ROADMAP Study 2-Year Results [PDF]

, 2017
OBJECTIVES The authors sought to provide the pre-specified primary endpoint of the ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients) trial at 2 years ...
Boyle, Andrew J., Bruckner, Brian A., Chuang, Joyce, Estep, Jerry D., Farrar, David J., Haas, Donald C., Horstmanshof, Douglas A., Kasirajan, Vigneshwar, Lee, Sangjin, Long, James W., Milano, Carmelo A., Rogers, Joseph G., Selzman, Craig H., Shah, Keyur B., Starling, Randall C., Stehlik, Josef   +15 more
core   +2 more sources

Left ventricular assist device.

New England Journal of Medicine, 2002
To the Editor: The value of angiotensin-converting– enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II–receptor antagonists; 35 to 40 percent received spironolactone ...
Jiménez-Navarro, Manuel, Molero, Encarnación, Teresa, Eduardo de   +2 more
openaire   +4 more sources

Synergistic Model of Cardiac Function with a Heart Assist Device [PDF]

, 2019
The breakdown of cardiac self-organization leads to heart diseases and failure, the number one cause of death worldwide. The left ventricular pressure–volume relation plays a key role in the diagnosis and treatment of heart diseases.
Bestel, Haken, Knudsen, Simaan, Tuzun
core   +2 more sources

Targeted myocardial gene expression in failing hearts by RNA sequencing

Journal of Translational Medicine, 2016
Background Myocardial recovery with left ventricular assist device (LVAD) therapy is highly variable and difficult to predict. Next generation ribonucleic acid (RNA) sequencing is an innovative, rapid, and quantitative approach to gene expression ...
Kajari Dhar, Alexandra M. Moulton, Eric Rome, Fang Qiu, Jeff Kittrell, Eugenia Raichlin, Ronald Zolty, John Y. Um, Michael J. Moulton, Hesham Basma, Daniel R. Anderson, James D. Eudy, Brian D. Lowes   +12 more
doaj   +1 more source

Left Ventricular Assist Device Outflow Cannula Obstruction

JACC: Case Reports, 2020
One of the dreaded complications of left ventricular assist device implantation is mechanical obstruction of the device secondary to pump thrombosis or mechanical outflow cannula obstruction.
Majid Asawaeer, MD, Sajid Kadir, MD, Arif Albulushi, MD, Anthony W. Castleberry, MD, Yiannis S. Chatzizisis, MD, PhD   +4 more
doaj   +1 more source

Design and characteristics of the prophylactic intra‐operative ventricular arrhythmia ablation in high‐risk LVAD candidates (PIVATAL) trial

Annals of Noninvasive Electrocardiology, 2023
Background The use of a Left Ventricular Assist Device (LVAD) in patients with advanced heart failure refractory to optimal medical management has progressed steadily over the past two decades. Data have demonstrated reduced LVAD efficacy, worse clinical
David T. Huang, Igor Gosev, Katherine L. Wood, Hima Vidula, William Stevenson, Frank Marchlinski, Gregory Supple, Sandip K. Zalawadiya, J. Peter Weiss, Roderick Tung, Wendy S. Tzou, Joshua D. Moss, Krishna Kancharla, Sunit‐Preet Chaudhry, Parin J. Patel, Arfaat M. Khan, Claudio Schuger, Guy Rozen, Michael S. Kiernan, Gregory S. Couper, Marzia Leacche, Ezequiel J. Molina, Anand D. Shah, Michael Lloyd, Jakub Sroubek, Edward Soltesz, Kalyanam Shivkumar, Casey White, Sinan Tankut, Brent A. Johnson, Scott McNitt, Valentina Kutyifa, Wojciech Zareba, Ilan Goldenberg   +33 more
doaj   +1 more source

Relationship between device acceptance and patient-reported outcomes in left ventricular assist device (LVAD) recipients [PDF]

, 2019
The number of Left Ventricular Assist Devices (LVADs) implanted each year is rising. Nevertheless, there are minimal data on device acceptance after LVAD implant, and on its relationship with patient-reported outcomes. We designed a cross-sectional study
Adamo, Luigi, Carney, Robert M., Clemenza, Francesco, Craddock, Heidi, Di Blasi, Maria, Ewald, Gregory, Girgenti, Rosario, Tosto, Crispino   +7 more
core   +2 more sources

Initial experience with the left ventricular assist device TransCoreTM [PDF]

, 2010
Cardiogenic shock is a condition associated to high mortality rates. For decades, the treatment consisted of vasoactive drugs and intra-aortic balloon pump.
Alves, Claudia Maria Rodrigues, Lima, Valter Correia De, Minohara, Stéfano Franco, Souza, Cristiano Freitas De   +3 more
core   +1 more source

Lawn Mower Versus Left Ventricular Assist Device

JACC: Case Reports, 2020
A 77-year-old man with history of ischemic cardiomyopathy and left ventricular assist device (LVAD) presented with abdominal pain after a lawn mower accident.
Vishal N. Rao, MD, MPH, Marat Fudim, MD, MHS, Andrew Griffin, MD, Jennifer A. Rymer, MD, MBA, W. Schuyler Jones, MD, Lynne M.H. Koweek, MD, Tony P. Smith, MD, Daniele Marin, MD, Adam D. DeVore, MD, MHS   +8 more
doaj   +1 more source

Slope of the anterior mitral valve leaflet: A new measurement of left ventricular unloading for left ventricular assist devices and systolic dysfunction [PDF]

, 2014
Left ventricular assist device (LVAD)-supported patients are evaluated routinely with use of transthoracic echocardiography. Values of left ventricular unloading in this unique patient population are needed to evaluate LVAD function and assist in patient
Bradley, Elisa A, Cedars, Ari M, Ewald, Gregory A, Joseph, Susan M, Martinez, Sara C, Novak, Eric L, Rasalingam, Ravi, Silvestry, Scott C   +7 more
core   +2 more sources